Merus (NASDAQ:MRUS) Price Target Increased to $93.00 by Analysts at Guggenheim
Merus (NASDAQ:MRUS – Free Report) had its target price boosted by Guggenheim from $57.00 to $93.00 in a report published on Tuesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other research analysts have also weighed in on the company. HC Wainwright reissued a buy rating […]
More Stories
Elevance Health, Inc. (NYSE:ELV) Short Interest Update
Elevance Health, Inc. (NYSE:ELV – Get Free Report) saw a large growth in short interest during the month of September....
Arm Holdings plc (NASDAQ:ARM) Given Average Recommendation of “Moderate Buy” by Analysts
Arm Holdings plc (NASDAQ:ARM – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the thirty...
AllianceBernstein Holding L.P. (NYSE:AB) Receives Consensus Rating of “Moderate Buy” from Brokerages
AllianceBernstein Holding L.P. (NYSE:AB – Get Free Report) has been given a consensus rating of “Moderate Buy” by the five...
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Sees Significant Decrease in Short Interest
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) was the recipient of a large drop in short interest during the...
180 Life Sciences Corp. (NASDAQ:ATNFW) Short Interest Down 15.9% in September
180 Life Sciences Corp. (NASDAQ:ATNFW – Get Free Report) was the recipient of a large decline in short interest in...
DoubleLine Opportunistic Credit Fund (NYSE:DBL) Short Interest Update
DoubleLine Opportunistic Credit Fund (NYSE:DBL – Get Free Report) was the recipient of a large growth in short interest in...